

# Yuka Tanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2160031/publications.pdf>

Version: 2024-02-01

48  
papers

866  
citations

567281

15  
h-index

501196

28  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. <i>Hepatology</i> , 2004, 39, 1321-1331.	7.3	126
2	Liver Sinusoidal Endothelial Cells Tolerize T Cells across MHC Barriers in Mice. <i>Journal of Immunology</i> , 2005, 175, 139-146.	0.8	68
3	Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique. <i>Transplantation</i> , 2005, 79, 1262-1267.	1.0	61
4	Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3226-35.	8.2	61
5	Adoptive Transfer of TRAIL-Expressing Natural Killer Cells Prevents Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. <i>Transplantation</i> , 2006, 82, 1712-1719.	1.0	60
6	Multiparameter Flow Cytometric Approach for Simultaneous Evaluation of Proliferation and Cytokine-Secreting Activity in T Cells Responding to Allostimulation. <i>Immunological Investigations</i> , 2004, 33, 309-324.	2.0	55
7	Liver Sinusoidal Endothelial Cells That Endocytose Allogeneic Cells Suppress T Cells with Indirect Allospecificity. <i>Journal of Immunology</i> , 2006, 177, 3615-3624.	0.8	40
8	Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study. <i>PLoS ONE</i> , 2019, 14, e0217586.	2.5	39
9	Liver sinusoidal endothelial cells have a capacity for inducing nonresponsiveness of T cells across major histocompatibility complex barriers. <i>Transplant International</i> , 2005, 18, 206-214.	1.6	29
10	Attenuation of Portal Hypertension by Continuous Portal Infusion of PGE1 and Immunologic Impact in Adult-to-Adult Living-Donor Liver Transplantation. <i>Transplantation</i> , 2013, 95, 1521-1527.	1.0	27
11	Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway. <i>Molecular Cancer Research</i> , 2020, 18, 1427-1440.	3.4	22
12	Quantitative Effect of Natural Killer Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy. <i>Cancer Immunology Research</i> , 2014, 2, 1142-1147.	3.4	20
13	A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates. <i>Transplantation Direct</i> , 2015, 1, 1-6.	1.6	20
14	Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation. <i>Human Immunology</i> , 2016, 77, 456-463.	2.4	17
15	PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice. <i>PLoS ONE</i> , 2017, 12, e0178765.	2.5	17
16	Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 589-599.	4.2	17
17	Cotransplantation of preactivated mesenchymal stem cells improves intraportal engraftment of islets by inhibiting liver natural killer cells in mice. <i>American Journal of Transplantation</i> , 2019, 19, 2732-2745.	4.7	16
18	Effect of Fc $\gamma$ 3 Receptor Polymorphism on Rituximab-Mediated B Cell Depletion in ABO-Incompatible Adult Living Donor Liver Transplantation. <i>Transplantation Direct</i> , 2017, 3, e164.	1.6	13

#	ARTICLE	IF	CITATIONS
19	Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice. <i>PLoS ONE</i> , 2017, 12, e0186997.	2.5	13
20	Strategies for Deliberate Induction of Immune Tolerance in Liver Transplantation: From Preclinical Models to Clinical Application. <i>Frontiers in Immunology</i> , 2020, 11, 1615.	4.8	12
21	Adoptive Transfer of Allogeneic Liver Sinusoidal Endothelial Cells Specifically Inhibits T-Cell Responses to Cognate Stimuli. <i>Cell Transplantation</i> , 2013, 22, 1695-1708.	2.5	11
22	Significant association between FOXP3 gene polymorphism and steroid-resistant acute rejection in living donor liver transplantation. <i>Hepatology Communications</i> , 2017, 1, 406-420.	4.3	10
23	Hepatic irradiation persistently eliminates liver resident NK cells. <i>PLoS ONE</i> , 2018, 13, e0198904.	2.5	10
24	Impact on biliary complications of donor abdominal aortic calcification among living donor liver transplantation: a retrospective study. <i>Transplant International</i> , 2020, 33, 1745-1753.	1.6	10
25	Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients. <i>Human Immunology</i> , 2017, 78, 357-362.	2.4	9
26	Everolimus enhances TRAIL-mediated anti-tumor activity of liver resident natural killer cells in mice. <i>Transplant International</i> , 2020, 33, 229-243.	1.6	8
27	Molecular Mismatch Predicts T Cell-Mediated Rejection and De Novo Donor-Specific Antibody Formation After Living Donor Liver Transplantation. <i>Liver Transplantation</i> , 2021, 27, 1592-1602.	2.4	8
28	Evidence for the Immunosuppressive Potential of Calcineurin Inhibitor-Sparing Regimens in Liver Transplant Recipients with Impaired Renal Function. <i>Journal of Transplantation</i> , 2011, 2011, 1-6.	0.5	7
29	Monitoring immune response after allogeneic transplantation of mesenchymal stem cells for osteochondral repair. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, e275-e286.	2.7	7
30	Fasting Enhances TRAIL-Mediated Liver Natural Killer Cell Activity via HSP70 Upregulation. <i>PLoS ONE</i> , 2014, 9, e110748.	2.5	6
31	Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. <i>Human Immunology</i> , 2014, 75, 1259-1267.	2.4	6
32	Risk Factors for Refractory Ascites After Living Donor Liver Transplant. <i>Transplantation Proceedings</i> , 2019, 51, 1516-1519.	0.6	4
33	Postoperative Portal Hypertension Enhances Alloimmune Responses after Living-Donor Liver Transplantation in Patients and in a Mouse Model. <i>Journal of Immunology</i> , 2019, 203, 1392-1403.	0.8	4
34	Development of a humanized mouse model to analyze antibodies specific for human leukocyte antigen (HLA). <i>PLoS ONE</i> , 2021, 16, e0236614.	2.5	4
35	Impacts of single nucleotide polymorphisms in Fc gamma receptor IIA ( <i>rs1801274</i> ) on lung transplant outcomes among Japanese lung transplant recipients. <i>Transplant International</i> , 2021, 34, 2192-2204.	1.6	4
36	Polymorphisms in CTLA-4 predict de novo donor specific antibody formation after kidney transplantation. <i>Human Immunology</i> , 2022, 83, 494-498.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Role of Invariant Natural Killer T Cells in Liver Sinusoidal Endothelial Cell-Induced Immunosuppression Among T Cells with Indirect Allopecificity. <i>Transplantation</i> , 2008, 85, 1060-1064.	1.0	3
38	Utility of Doppler Ultrasonography in Liver Transplantation With Celiac Axis Compression Syndrome: A Case Report. <i>Transplantation Proceedings</i> , 2019, 51, 3103-3106.	0.6	3
39	Adoptive immunotherapy overcomes genetic susceptibility to bloodstream infections due to fcÎ³ receptor polymorphisms after liver transplantation. <i>American Journal of Transplantation</i> , 0, , .	4.7	3
40	Acute portal hypertension using portal vein ligation abrogates TRAIL expression of liver-resident NK cells. <i>Hepatology Communications</i> , 2022, 6, 2551-2564.	4.3	3
41	Successful multidisciplinary treatment of refractory cytomegalovirus infection after living donor liver transplantation using mixed lymphocyte reactions: report of a case. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 38-42.	0.8	2
42	Viability of Airborne Tumor Cells during Excision by Ultrasonic Device. <i>Surgery Research and Practice</i> , 2017, 2017, 1-5.	0.5	2
43	Identification of Aggravation-Predicting Gene Polymorphisms in Coronavirus Disease 2019 Patients Using a Candidate Gene Approach Associated With Multiple Phase Pathogenesis: A Study in a Japanese City of 1 Million People. , 2021, 3, e0576.		2
44	Management of Refractory Ascites for Liver Transplant Candidates: A Novel Cell-free and Concentrated Ascites Reinfusion Therapy. <i>Transplantation Proceedings</i> , 2019, 51, 2740-2744.	0.6	1
45	TLR-MyD88 signaling blockades inhibit refractory B1b cell immune responses to transplant-related glycan antigens. <i>American Journal of Transplantation</i> , 2021, 21, 1427-1439.	4.7	1
46	Analysis of Risk Factors Affecting Incidence of Osteoporosis and Fragility Fractures in Liver Transplant Recipients. <i>Annals of Transplantation</i> , 2021, 26, e925475.	0.9	1
47	Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2020, 52, 600-603.	0.6	0
48	B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4+ T cell responses in highly sensitized transplant recipients. <i>Scientific Reports</i> , 2021, 11, 18180.	3.3	0